Ronald Alvarez, MD

University of Alabama

AlvarezRonald D. Alvarez, MD, is Professor and Director of the Division of Gynecologic Oncology at the University of Alabama at Birmingham (UAB).  He received his B.S. in Zoology from Louisiana State University in 1979 and his M.D. from Louisiana State University Medical Center in New Orleans in 1983. His postgraduate training included a residency in Obstetrics and Gynecology (1987) and fellowship in Gynecologic Oncology (1990) both completed at UAB.  After completing his training, he remained on the faculty of the UAB Department of Obstetrics and Gynecology, where he currently serves as Vice-Chairman and holds the Ellen Gregg Shook Culverhouse Chair.

His long-term research interests have included the development of novel therapeutics for ovarian cancer and new screening and prevention strategies for cervical cancer.  He has been the recipient of several NCI and other industry funded grants in support of his research in gene therapeutics for ovarian cancer and he is currently a co-principal investigator in cervical neoplasm vaccine projects included in the John Hopkins/UAB Cervical SPORE.

Dr. Alvarez has published over 200 articles in various peer-reviewed journals and he is on the editorial board of Gynecologic Oncology. He currently serves as co-chair of Gynecologic Oncology Group Protocol Development Committee and has served until recently on its Board of Directors.  He is on the Gynecologic Oncology Division of the American Board of Obstetrics and Gynecology and has served on study sections for the NCI and the Department of Defense Ovarian Cancer Research Program. He has also served on the Executive Committee of the Gynecologic Cancer Foundation and is currently President of the Society of Gynecologic Oncology.

Spotlight

Visit the Sisterhood of Survivorship page to read “Dena’s Story” — by a vulvar cancer survivor who has shared her story and wise words, and channeled her energy into her National Race to End Women’s Cancer team.

Awareness

Vaccine efficacy against vulvar infection with HPV 16/18 was comparable to the efficacy found against cervical infection 4 years after vaccination, according to researchers with the National Cancer Institute.

Research

The Foundation has published its 2014-2015 Research Grants and Awards Booklet with Applications. Please consider applying to become part of an elite group of physician-scientists committed to the well-being of women at risk for/affected by gyn malignancies.

Education

The next Ovarian Cancer Survivors Course will be Saturday, July 26, 2014 in Boston. For more information on courses, click here.